Value-Added Medicines with
clinical impact
Galenicap is an emerging pharmaceutical company specialized in the development of innovative, clinically validated Value-Added Medicines (VAMs) across large, high-impact therapeutic areas. By integrating scientific insight, clinical evidence, and patient-centered design, we develop medicines that deliver real therapeutic value and measurable improvements in care, globally.
Product portfolio
Galenicap is building a scalable product development engine that transforms validated science through drug reformulation and repurposing strategies into meaningful therapeutic innovations for patients.
Our approach combines strategic program selection, efficient and agile development, and targeted clinical investment to accelerate the journey from concept to clinical validation and patient impact.
We are currently advancing multiple active programs across major disease areas, including CNS disorders, stroke, oncology, cardiovascular diseases, infectious diseases, obesity, and women’s health.
We turn validated science - often trapped in academia or missed commercially - in real solutions for patients
Everyone counts
Our vision is to improve healthcare by expanding access to affordable, patient-centered medicines.
At Galenicap, we are deeply committed to responsible business practices rooted in strong governance and meaningful social impact. We champion health equity, fair medicine pricing, transparent leadership, and a culture of diversity and inclusion.
We are proud that our team members, collaborators, partners, and shareholders are united in upholding these values.
Latest news & events
Galenicap enters into drug repurposing collaboration with US university
​
June 17, 2025
Galenicap BV and Neurevo GmbH created Glicothera BV, a specialty pharma focused on a new neuroprotective agent for stroke
May 13, 2025
Galenicap co-founded Aclathera BV, a specialty pharma dedciated to the development of new cancer treatments
March 28, 2025